Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A recently recognized variant of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that lacks somatic hypermutations of the Immunoglobulin heavy chain (IGH) genes, implying pregerminal center B-cell origin. Microarray gene expression profiling studies have demonstrated the expression of ZAP-70 gene (Syk family tyrosine kinase) in this subset of CLL/CLL. Patients with this variant of CLL/SLL have an unfavorable prognosis compared to those with somatic hypermutations of the IGH genes, with a median survival of approximately 6-8 years.
Biomarker and diagnostic research for pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma has been reported in the published literature.
1 FDA-approved treatment is available for pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma, including BENDAMUSTINE HYDROCHLORIDE (BENDAMUSTINE HYDROCHLORIDE, approved 2022).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
No clinical trials have been registered for pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma.
28 publications have been identified in PubMed for pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma. Research spans Diagnostic / Biomarker (25%), Review / Meta-Analysis (21%), and Clinical Trial Publication (21%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 7 | 25% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:36 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
BENDAMUSTINE HYDROCHLORIDE |
BENDAMUSTINE HYDROCHLORIDE |
— |
2022 |
Available |
View trials for pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma
Research summaries |
6 |
21% |
Clinical study results | 6 | 21% |
Laboratory research | 4 | 14% |
Disease patterns and progression | 4 | 14% |
Patient case studies | 1 | 4% |
Böttcher M (2026). [PMID: 41486278](https://pubmed.ncbi.nlm.nih.gov/41486278/). *Signal Transduct Target Ther*. [Basic Science / Preclinical]
Visentin A (2026). [PMID: 41275991](https://pubmed.ncbi.nlm.nih.gov/41275991/). *Crit Rev Oncol Hematol*. [Review / Meta-Analysis]
Dupont M (2026). [PMID: 41117149](https://pubmed.ncbi.nlm.nih.gov/41117149/). *Br J Haematol*. [Basic Science / Preclinical]
Chakraborty SR (2026). [PMID: 41595525](https://pubmed.ncbi.nlm.nih.gov/41595525/). *Genes (Basel)*. [Diagnostic / Biomarker]
Barrett A (2025). [PMID: 40127387](https://pubmed.ncbi.nlm.nih.gov/40127387/). *Blood Adv*. [Review / Meta-Analysis]
Guo Z (2025). [PMID: 40355356](https://pubmed.ncbi.nlm.nih.gov/40355356/). *Zhonghua Xue Ye Xue Za Zhi*. [Diagnostic / Biomarker]
Sabatini P (2025). [PMID: 40734655](https://pubmed.ncbi.nlm.nih.gov/40734655/). *Am J Clin Pathol*. [Diagnostic / Biomarker]
Zhang ZL (2025). [PMID: 40134196](https://pubmed.ncbi.nlm.nih.gov/40134196/). *Zhonghua Xue Ye Xue Za Zhi*. [Diagnostic / Biomarker]
Alves D (2025). [PMID: 40282492](https://pubmed.ncbi.nlm.nih.gov/40282492/). *Cancers (Basel)*. [Diagnostic / Biomarker]
Vit F (2025). [PMID: 40533497](https://pubmed.ncbi.nlm.nih.gov/40533497/). *Leukemia*. [Diagnostic / Biomarker]